28.07.2017 • News

Solenis Acquires Nopco Colombiana

(c) Lichtmeister/Shutterstock
(c) Lichtmeister/Shutterstock

Following an agreement signed in May, US specialty chemical company Solenis has completed the acquisition of Nopco Colombiana. Financial details were not disclosed.  Headquartered in Medellin, Colombia, Nopco Colombiana was originally Solenis’ pulp and paper specialty chemical distributor in Central and South America.

The South American company is a leading producer and supplier of specialized chemical solutions for water-intensive industries such as pulp and paper, oil and gas, food and beverage, among others. Its products include wet strength resins, antiscalants, dispersants and defoamers, which are supplied to markets in Colombia, Ecuador and Peru.

“This acquisition represents Solenis’ commitment to direct channel investments in strategic growth markets. The addition of Nopco Colombiana allows the US firm to expand its capabilities to serve the growing process and water-treatment markets in Central and South America,” said John Panichella, president and CEO of Solenis, said.

The deal follows Solenis’ acquisition of Nopco Holding, a Norwegian producer of specialty chemicals for the pulp and paper industry, in September 2016.

Solenis was formerly known as Ashland Water Technologies. The name change coincided with the acquisition of Ashland Water Technologies in July 2014 by a fund managed by private equity company Clayton, Dubilier & Rice for around $1.8 billion. Solenis said it is focused on growing the business in the areas of process and water technologies.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.